Why the study?
Does withholding versus continuing ACEIs or ARBs before noncardiac surgery reduce the 30-day composite outcome of all-cause death, myocardial injury, and stroke?
Does withholding versus continuing ACEIs or ARBs before noncardiac surgery reduce the 30-day composite outcome of all-cause death, myocardial injury, and stroke?
Answers are grounded in this paper and cite their sources.
Withholding ACEIs/ARBs may lower perioperative risk; leaves open need for RCTs before practice change.
(Abstracted from Anesthesiology, 126(1):16–27, 2017) The purpose of this international prospective cohort study was to assess the effect of withholding angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on the risk of 30-day composite outcome of all-cause death, myocardial injury following noncardiac surgery (MINS), and stroke, as well as to determine the relationship between withholding ACEIs/ARBs and perioperative hypotension.
No takes yet. Share an insight, caveat, or question.
Roshanov et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: